DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________Evaluation of the effects of age, prior exposure, and previous 
vaccination on the B cell response to inactivated influenza 
vaccine in healthy adults and children
DMID Protocol Number: 
16-0101
Sponsored by:
[CONTACT_4461] (NIAID)
DMID Funding Mechanism:
HHSN266200700008C
Site Principal Investigator:
[INVESTIGATOR_609113], MD
University of [COMPANY_002]ster Medical Center
DMID Clinical Project Manager:
Melinda Tibbals, RAC, CCRA
Version: 5.0
25 January 2021
_____________________________________________________________________________________________
iStatement of Compliance
The study will be carried out in accordance with Good Clinical Practice (GCP) as 
required by [CONTACT_716]:
U.S. Code of Federal Regulations applicable to clinical studies (45 CFR 46)
21 CFR 312
ICH GCP E6
Completion of Human Subjects Protection Training
NIH Clinical Terms of Award
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
iiSIGNATURE [CONTACT_287560], and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines.
Principal Investigator:
[INVESTIGATOR_14586]: Date:
Angela Branche, MD
Principal Investigator, University of [COMPANY_002]ster
CEIRS
 
_____________________________________________________________________________________________
iiiStatement of Compliance ...............................................................................................................i
Signature [CONTACT_3490] ..............................................................................................................................ii
List of Abbreviations......................................................................................................................vi
Protocol Summary ....................................................................................................................…vii
1 PROTOCOL SUMMARY.....................................................................................................vii
2 Key Roles .............................................................................................................................1
3 Background Information and Scientific Rationale.................................................................3
3.1 Background Information............................................................................................3
3.2 Scientific Rationale ...................................................................................................3
3.3 Potential Risks and Benefits .....................................................................................4
3.3.1 Potential Risks ..............................................................................................4
3.3.2 Known Potential Benefits ..............................................................................5
4 Objectives and Outcome Measures......................................................................................5
4.1 Study Objectives .......................................................................................................5
4.2 Outcome Measures...................................................................................................6
5 Study Design ........................................................................................................................6
6 Study Population...................................................................................................................7
6.1 Inclusion Criteria .......................................................................................................8
6.2 Exclusion Criteria ......................................................................................................8
6.3 Handling of Withdrawals .........................................................................................10
6.4 Termination of Study...............................................................................................10
7 Study Intervention/Investigational Product .........................................................................[ADDRESS_807723] Storage and Stability......................................................................11
7.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product....................................................................................................................11
7.3 Modification of Study Intervention/Investigational Product for a Participant ...........11
7.4 Accountability Procedures for the Study Intervention/Investigational Product(s)....11
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
iv7.5 Assessment of Participant Compliance with Study Intervention/Investigational 
Product....................................................................................................................12
7.6 Concomitant Medications/Treatments ....................................................................12
8 Study Schedule...................................................................................................................12
8.1 Vaccination/Baseline (Defined as Day 0)................................................................12
8.2 Follow-up and Final Visits .......................................................................................13
8.2.1 Day 7 visit (+/- 1 day) ..................................................................................13
8.2.2 Day 28 visit (+/- 3 days) ..............................................................................14
8.2.3 Day 90 visit (+/- 7 days) ..............................................................................14
8.2.4 Blood Volumes in Children..........................................................................15
8.2.5 Surveillance for acute influenza ..................................................................15
8.3 Early Termination Visit ............................................................................................16
8.4 Unscheduled Visit ...................................................................................................16
9 Study Procedures and evaluations.....................................................................................17
9.1 Clinical Evaluations.................................................................................................17
9.2 Laboratory Evaluations/Assays...............................................................................17
9.2.1 Immunogenicity Evaluations .......................................................................17
9.2.2 Specimen Collection, Preparation, Handling and Shippi[INVESTIGATOR_007].........................19
10 Assessment of Safety.........................................................................................................19
10.1 Specification of Safety Parameters.........................................................................19
11 Clinical monitoring ..............................................................................................................20
11.1 Site Monitoring Plan................................................................................................20
12 Statistical considerations ....................................................................................................20
12.1 Study Hypothesis ....................................................................................................20
12.2 Sample Size Considerations...................................................................................20
12.3 Planned Interim Analyses (if applicable).................................................................21
12.3.1 Safety Review .............................................................................................21
12.3.2 Immunogenicity or Efficacy Review ............................................................21
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
v12.4 Final Analysis Plan..................................................................................................21
13 Source Documents and Access to Source Data/Documents .............................................22
14 Quality Control and Quality Assurance...............................................................................22
15 Ethics/Protection of Human Subjects .................................................................................[ADDRESS_807724] ......................................................................................23
15.3 Informed Consent Process .....................................................................................23
15.3.1 Informed Consent/Assent Process (in Case of a Minor) .............................24
15.4 Exclusion of Women, Minorities, and Children (Special Populations) ....................[ADDRESS_807725] Keepi[INVESTIGATOR_007] ...................................................................................25
16.1 Data Management Responsibilities ........................................................................26
16.2 Data Capture Methods............................................................................................26
16.3 Types of Data..........................................................................................................26
16.4 Timing/Reports........................................................................................................26
16.5 Study Records Retention ........................................................................................27
16.6 Protocol Deviations .................................................................................................27
17 Publication Policy................................................................................................................27
18 Literature References .........................................................................................................28
19 Supplement/Appendices.....................................................................................................29
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
viAE Adverse Event/Adverse Experience
ASC Antibody Secreting Cell
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CO Contracting Officer
COR Contracting Officer Representative
CRF Case Report Form
DMID Division of Microbiology and Infectious Diseases 
DSMB Data and Safety Monitoring Board
FWA Federalwide Assurance
GFPD Genome Fragment Phage Display
GCP Good Clinical Practice
HAI Hemagglutination-Inhibition
ICF Informed Consent Form
ICH International Conference on Harmonisation
IEC Independent or Institutional Ethics Committee
IRB Institutional Review Board
JAMA Journal of the American Medical Association
MBC Memory B Cell
MN Microneutralization
MOP Manual of Procedures
N Number (typi[INVESTIGATOR_33891])
NEJM New England Journal of Medicine
NIAID National Institute of Allergy and Infectious Diseases, NIH, 
DHHS
NIH National Institutes of Health
OCRA Office of Clinical Research Affairs, DMID, NIAID, NIH, DHHS
OHRP Office for Human Research Protections
ORA Office of Regulatory Affairs, DMID, NIAID, NIH, DHHS
PI [INVESTIGATOR_486284]/Serious Adverse Experience
SMC Safety Monitoring Committee
SOP Standard Operating Procedure
SPR Surface Plasmon Resonance
WHO World Health Organization
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
vii1 PROTOCOL SUMMARY
Title: Evaluation of the effects of age, prior exposure and previous vaccination 
on the B cell response to inactivated influenza vaccine in healthy adults 
and children.
Population: 240 Healthy adults and children ages 9 and over
Number of Sites: Single site study
Study Duration : 5 years
Participant Duration: 6 months
Objectives:
Primary Objective
To evaluate the relationship between first influenza A virus exposure (inferred by [CONTACT_654]), vaccine 
history, and baseline serum antibody  response to seasonal influenza vaccine in healthy adults 
and children.
Primary Endpoint:
Measurement of the magnitude and specificity of the serum antibody responses by 
[CONTACT_609119] (HAI) and microneutralization (MN) at day 7 and 28, overall and 
stratified by [CONTACT_551], vaccine history, and baseline serum antibody level.

Serum antibody response on day [ADDRESS_807726] symptomatic influenza 
and the immune response to infection in vaccinated individuals by [CONTACT_609120].
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
viiiSecondary Endpoints
Description of demographic and clinical characteristics and immune response to vaccination 
among subjects who develop symptomatic influenza (Vaccine Failures) and among subjects 
who do not.
Exploratory Objective
To evaluate the relationship between first influenza A virus exposure (inferred by [CONTACT_654]), vaccine 
history, and Memory B cell (MBC) specificity, and the magnitude and breadth of the subsequent 
B cell response to seasonal influenza vaccine in healthy adults and children.
Exploratory Endpoints
Frequency and specificity of peripheral blood antibody secreting cells (ASC) on day [ADDRESS_807727] vaccination (initial response), overall and stratified by [CONTACT_551], vaccine history, 
and baseline serum antibody level 
Frequency and specificity of peripheral blood memory B cells (PMBC) on day [ADDRESS_807728] 
vaccination (memory response), overall and stratified by [CONTACT_551], vaccine history, and 
baseline serum antibody level
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
ixSchematic of Study Design:
* Note:  For children weighing less than [ADDRESS_807729]
[COMPANY_002]ster, NY [ZIP_CODE]
Phone [PHONE_12609]
Fax [PHONE_12610]
Email:[EMAIL_11588]
DMID Clinical Project Manager:Melinda Tibbals, RAC, CCRA
DMID, NIAID, NIH 
[ADDRESS_807730]
Rockville, MD  [ZIP_CODE]
Tel: [PHONE_12611] 
Email: [EMAIL_11589]
DMID Scientific Lead:Erik J. Stemmy, Ph.D.
DMID, NIAID, NIH 
[ADDRESS_807731]
Rockville, MD  [ZIP_CODE] 
Tel:  [PHONE_12612]
Fax:  [PHONE_12613]
Email:  [EMAIL_11590]
DMID Medical MonitorVenus Shahamatdar, MD
DMID, NIAID, NIH 
[ADDRESS_807732], Room 7E54
Rockville, MD [ZIP_CODE]
Phone: [PHONE_2600]
Email: [EMAIL_2262]
DMID Medical OfficerTrinka Coster, MD, MSDMID, NIAID, NIH
[ADDRESS_807733]
Rockville, Maryland [ZIP_CODE]
Phone: [PHONE_12614]
E-mail: [EMAIL_11591]
DMID 16-[ADDRESS_807734]
[COMPANY_002]ster NY
Phone [PHONE_12615]
Fax [PHONE_12616]
Email:  David [EMAIL_11592]
Mark Sangster PhD
University of [COMPANY_002]ster
[ADDRESS_807735]
[COMPANY_002]ster NY
Phone [PHONE_12617]
Fax 585-273-[ZIP_CODE]
Email:  Mark [EMAIL_11593]
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
33 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE 
3.1 Background Information 
Inactivated influenza vaccines (IIVs) have been in use in the US and worldwide for the 
prevention of illness due to seasonal and pandemic influenza since their licensure 
approximately [ADDRESS_807736] suggested 
that vaccine efficacy is higher in those who were not vaccinated in the previous season than in 
those who were [1, 2].  Other studies have not seen this association [3].  The mechanisms by 
[CONTACT_609121], but would have obvious implications for the design of new influenza vaccines and 
vaccine strategies.
3.[ADDRESS_807737] likely occurring during childhood, affects later-in-life immune responses 
to influenza vaccination. Recent data in the literature [4, 5], and our own preliminary data 
suggest that initial encounters with influenza have a long lasting effect on circulating antibodies 
and the specificity of the memory B cell repertoire.  This protocol will test whether qualitative 
and quantitative differences in circulating antibodies and memory B cells can strongly influence 
subsequent immune responses to seasonal influenza vaccines. This protocol will perform 
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
4parallel assessment of antibody, ASC, and memory B cells over the course of an immune 
response to determine how vaccination modifies the B cell and antibody repertoires. As a 
measure of the cells responding to the vaccination, our assays will focus on the acutely 
activated antibody-secreting B cells (ASC, plasmablasts) and antibodies secreted (day 7). 
Because these ASC can be short lived, later in the response this protocol will also look at in 
vitro reactivated memory B cells and secreted antibodies at days 0, 28, and 90 as measures of 
the adapted responses before and after vaccination. Serum antibodies will also be tested for 
function, specificity, amount, and quality by [CONTACT_609122], as well as more 
sophisticated assays described below (ELISA, SPR, GFPDL).
3.3 Potential Risks and Benefits
3.3.1 Potential Risks
The risks and discomforts of this study include risks associated with the vaccine, administration 
of the vaccine, the risks associated with study procedures (blood drawing and nasal and throat 
swabs) and possible loss of confidentiality.
In placebo-controlled trials in adults, inactivated seasonal vaccines are associated with mild 
local pain at the site of administration.  Systemic symptoms like fever and malaise occur at rates 
equal to placebo.  According to the package insert, in adults, the most common (≥10%) 
injection site adverse reaction was pain (36%); the most common systemic adverse events were 
muscle aches (16%), headache (16%), and fatigue (16%). In children aged 3 through 17 years, 
the injection site adverse reactions were pain (44%), redness (23%), and swelling (19%). In 
children aged [ADDRESS_807738] common (≥10%) systemic adverse events were 
drowsiness (17%), irritability (17%), and loss of appetite (16%); in children aged [ADDRESS_807739] common systemic adverse events were fatigue (20%), muscle aches 
(18%),headache (16%), arthralgia (10%), and gastrointestinal symptoms (10%).
During the swine influenza vaccine campaign of 1976, about 10 per 1,000,000 vaccine 
recipi[INVESTIGATOR_609114]-Barré 
Syndrome (GBS).  In the subsequent decade, no association between seasonal influenza 
vaccine and GBS was found. More extensive investigations of this potential association 
occurring in the 1990s revealed that there was a small but detectable risk of GBS in the 6 weeks 
following seasonal influenza immunization: an attributable risk of approximately 1 per 1,000,000, 
adjusted for potential confounders.  In the period since the Vaccine Adverse Event Reporting 
System (VAERS) was established in 1990, the rates of GBS reports following influenza 
vaccination have declined substantially. The annual reporting rate in that period was highest in 
the 1993-1994 influenza season (1.7 per 1,000,000 vaccinees) and lowest in the last season 
analyzed in the report, 2002-2003 (0.4 per 1,000,000 vaccinees) [6]. No cases of GBS have 

DMID 16-[ADDRESS_807740] influenza A virus exposure (inferred by [CONTACT_654]), vaccine 
history, and baseline serum antibody response to seasonal influenza vaccine in healthy adults 
and children
Secondary Objectives
Evaluate factors related to failure of vaccine to provide protection against symptomatic 
influenza and the immune response to infection in vaccinated individuals by [CONTACT_609123].
Exploratory Objectives
DMID 16-[ADDRESS_807741] influenza A virus exposure (inferred by [CONTACT_654]), vaccine 
history, and Memobry B cell (MBC) specificity, and the magnitidue and breath of the subsequent 
B cell response to seasonal influenza vaccine in healthy adults and children
4.2 Outcome Measures
Primary Outcome Measures:
Measurement of the magnitude and specificity of the serum antibody responses by 
[CONTACT_609119] (HAI) and microneutralization (MN) at day 7 and 28, overall and 
stratified by [CONTACT_551], vaccine history, and baseline serum antibody level 
Serum antibody response on day 90 after vaccination by [CONTACT_609124]
Description of demographic and clinical characteristics and immune response to 
vaccination among subjects who develop symptomatic influenza (Vaccine Failures) and 
among subjects who do not.
Exploratory Outcome Measures
Frequency and specificity of peripheral blood antibody secreting cells (ASC) on day [ADDRESS_807742] vaccination (initial response), overall and stratified by [CONTACT_551], vaccine history, 
and baseline serum antibody level 
Frequency and specificity of peripheral blood memory B cells (PMBC) on day [ADDRESS_807743] 
vaccination (memory response), overall and stratified by [CONTACT_551], vaccine history, and 
baseline serum antibody level 
5 STUDY DESIGN
The study will be designed as a prospective surveillance of the immune response to seasonal 
vaccination in healthy adults of varying ages.  A schematic of the study design is shown below:
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
7
* Note for children weighing less than [ADDRESS_807744] of up to 240 medically stable adults and children ages 9 and 
older enrolled over 5 years.  Recruitment will be stratified in an attempt to achieve an even 
distribution of ages with a goal of 30 subjects in each of 8 age strata (9-19, 20-29…80+)
DMID 16-[ADDRESS_807745] meet all of the following inclusion criteria to participate in this study:
1. Aged equal to or greater than [ADDRESS_807746] be in good health, as determined by: [CONTACT_9870]; and targeted 
physical examination, when necessary, based on medical history.  Stable medical or 
psychiatric condition is defined as: no recent increase in prescription medication, dose, or 
frequency of medication in the last [ADDRESS_807747]/parent has provided informed consent/assent prior to any study procedures.
5. Subjects who have not received seasonal flu vaccine for the current year.
6.2 Exclusion Criteria
Subjects who meet any of the following exclusion criteria at baseline cannot participate in the 
study:
1. Subject report of known hypersensitivity to allergy to components of the study vaccine or 
other components of the study vaccine.
2. Subject report of known latex allergy
3. Subject report of a history of severe reactions following previous immunization with licensed 
or unlicensed influenza virus vaccines. 
4. Subject report of a history of Guillain-Barre syndrome within [ADDRESS_807748] has an active neoplastic disease (excluding non-melanoma skin cancer or 
prostate cancer that is stable in the absence of therapy) or a history of any hematological 
malignancy.  For this criterion, “active” is defined as having received treatment within the 
past [ADDRESS_807749] taken high-dose inhaled corticosteroids within 30 days prior to study vaccination.
High-dose defined as per age as using inhaled high dose per reference chart 
https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/quick-reference-
html#estimated-comparative-daily-doses
9. The subject received immunoglobulin or another blood product within the [ADDRESS_807750] has an acute or chronic medical condition that, in the opi[INVESTIGATOR_609115]-investigator, would render vaccination unsafe or would interfere with the 
evaluation of responses. These conditions include any acute or chronic medical disease or 
conditions defined as persisting for 3 months (defined as 90 days) or longer, that would 
place the subject at an unacceptable risk of injury, render the subject unable to meet the 
requirements of the protocol, or may interfere with the evaluation of responses of the 
subject’s successful completion of the study.   
12. Subjects with an active infection or that has an acute illness or an oral temperature greater 
than 99.9F (37.7C) within 3 days prior to enrollment or vaccination.  Subjects who had an 
acute illness that was treated symptoms resolved are eligible to enroll as long as treatment 
is completed and symptoms resolved > [ADDRESS_807751] is currently participating or plans to participate in a study that involves an 
experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has 
received an experimental agent within [ADDRESS_807752] a medical procedure during the upcoming 8 weeks that estimates 
blood loss to exceed 400 cc for adults or for children would exceed 3 ml/kg. 
6.[ADDRESS_807753] to follow-
up after receiving the assigned vaccine will not be replaced.  Participants who consented to the 
study but did not receive the influenza vaccine will be replaced. These subjects will be 
considered as screen failures. 
6.4 Termination of Study 
Although the study sponsor has every intention of completing the study, the sponsor reserves 
the right to terminate the study at any time for clinical or administrative reasons.  Reasons for 
termination include, but are not limited to, study closure due to internal safety review and 
recommendation, or at the discretion of DMID.
7 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT
7.[ADDRESS_807754] Description
  Quadrivalent (IIV-4) split virion licensed vaccine produced in embryonated hen’s 
eggs and administered intramuscularly at a dose of not less than 15 ug of HA (as determined by 
[CONTACT_609125]) of the following 4 influenza virus strains (2 A strains and 2 B strains): 
A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), 
A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a 
B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
 Quadrivalent (IIV-4) split virion licensed vaccine produced in embryonated hen’s 
eggs and administered intramuscularly at a dose of not less than 15 ug of HA (as determined by 
[CONTACT_609125]) of the following 4 influenza virus strains (2 A strains and 2 B strains): 
A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), 
A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a 
B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.

DMID 16-[ADDRESS_807755] Storage and Stability
Influenza vaccine will be stored according to manufacturer’s directions in secure, limited-access 
temperature monitored refrigerator environment at 2°C to 8°C (36°F to 46°F) until needed.  DO 
NOT FREEZE.  The temperature of the storage unit will be monitored during the duration of the 
trial, and documentation of proper dedicated storage will be maintained.  In the event of 
accidental deep-freezing or disruption of the cold chain, vaccines will not be administered; and 
the PI [INVESTIGATOR_494655].  
7.2 Dosage, Preparation and Administration of Study 
Intervention/Investigational Product
Vaccine will be formulated in single dose vials or syringes and will not require additional 
formulation prior to administration.  A vaccine dose of 0.5mL will be administered by a clinical 
research nurse intramuscularly (IM) in the subject’s preferred deltoid (upper arm) per the 
manufacturer’s instructions.

DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
127.3 Modification of Study Intervention/Investigational Product 
for a Participant
As there is only a single dose administered, there will be no dose or schedule modifications for 
any subject.
7.4 Accountability Procedures for the Study 
Intervention/Investigational Product(s)
Records of vaccine receipt and dispensation to the study subject as well as storage and 
destruction of the vaccine will be maintained according to existing standard operating 
procedures (SOPs)
7.5 Assessment of Participant Compliance with Study 
Intervention/Investigational Product 
Not applicable, single intervention within the vaccine clinic only.
7.6 Concomitant Medications/Treatments
Administration of any medication or therapi[INVESTIGATOR_164623]’s welfare will 
be recorded and documented in the subject’s source documentation.  Concomitant medications 
will include all medications taken within [ADDRESS_807756]’s during each follow up visit. If any of 
these become applicable during the study, it will be noted in the subject’s record.
1. Use of any investigational drug or investigational vaccine other than the study article.
2. Administration of chronic (defined as more than 14 days) immunosuppressants or other 
immune-modifying drugs (topi[INVESTIGATOR_174841]).
3. Receipt of a licensed vaccine.
4. Receipt of immunoglobulins and/or any blood products.
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
138 STUDY SCHEDULE
8.1 Vaccination/Baseline (Defined as Day 0)
At the baseline visit, subjects will be enrolled in the study and if they meet the entry criteria will 
receive influenza vaccine.  The following procedures will be performed at the baseline visit.  
The study will be explained to the subject/parent, and the informed consent document 
will be signed.  Subjects/Parents will keep a signed copy of the informed consent for 
their information. Subjects 9 to 12 will be read an Assent Script and subjects 13-17 will 
sign an Assent Form.
A medical history will be obtained including history of prior Influenza vaccinations, and 
details recorded in the case report form.
Concomitant medications will be reviewed and recorded.
A targeted physical examination will be performed, if indicated by [CONTACT_198669], 
directed at the relevant portions of the exam.
The entry criteria will be reviewed and it will be verified that the subject meets all entry 
criteria.  If the subject does not meet the entry criteria, the subject will be discontinued 
from the study, or can be rescreened in the case of entry criteria mandating temporary 
delays.
Subjects will be considered enrolled if they have signed the consent form.  However, only 
subjects who meet the entry criteria will be vaccinated and continue in the study.  The 
reasons for screen failure will be recorded for all subjects who do not meet the entry criteria.  
If the entry criteria are met:
30 mL of blood will be obtained from an arm vein (3 x 10 mL green top tubes) for 
isolation of Peripheral Blood Mononuclear Cells (PBMC).
8 mL of blood will be obtained from and arm vein (1 x 8 mL red top tube) for serum.
For children who weigh less than 100 lbs, only 15 mL of blood will be drawn
Subjects will receive vaccine by [CONTACT_609126].
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
14Subjects will be observed in the clinic for [ADDRESS_807757] vaccination for development of 
acute adverse events
8.2 Follow-up and Final Visits
8.2.1 Day 7 visit (+/- 1 day)
Subjects will return one week after vaccination for the day 7 visit.  Because the timing of 
assessment of the cellular response to vaccination is critical, every effort will be made to 
ensure that subjects return on day 7.  Visits that occur out of window will still be 
evaluated but will not be included in the primary analysis.  On the day 7 visit, the 
following procedures will be done:
Interval medical history will be obtained including concomitant medications, 
reviewing any new events since the last visit.
The site of vaccination will be examined.  If indicated by [CONTACT_9870], a 
directed physical exam will also be performed. 
Any adverse events (AE) will be recorded and appropriate corrective actions 
taken if indicated.
30 mL of blood will be obtained from an arm vein (3 x 10 mL green top tubes) for 
isolation of Peripheral Blood Mononuclear Cells (PBMC).
8 mL of blood will be obtained from and arm vein (1 x 8 mL red top tube) for 
serum.
For children who weigh less than 100 lbs, only 15 mL of blood will be drawn
8.2.2 Day 28 visit (+/- 3 days)
Subjects will return for follow up approximately 28 days after vaccination for assessment 
of the immune response.  At that visit, the following procedures will be performed:
Interval medical history will be obtained including concomitant medications, 
reviewing any new events since the last visit.
If indicated by [CONTACT_9870], a directed physical exam will also be performed. 
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
15Any adverse events (AE) will be recorded and appropriate corrective actions 
taken if indicated.
30 mL of blood will be obtained from an arm vein (3 x 10 mL green top tubes) for 
isolation of Peripheral Blood Mononuclear Cells (PBMC).
8 mL of blood will be obtained from and arm vein (1 x 8 mL red top tube) for 
serum.
For children who weigh less than 100 lbs, only 15 mL of blood will be drawn
8.2.3 Day 90 visit (+/- 7 days)
Subjects will return approximately [ADDRESS_807758]:
Interval medical history will be obtained, including concomitant medications, 
reviewing any new events since the last visit.
If indicated by [CONTACT_9870], a directed physical exam will also be performed. 
Any adverse events (AE) will be recorded and appropriate corrective actions 
taken if indicated.
30 mL of blood will be obtained from an arm vein (3 x 10 mL green top tubes) for 
isolation of Peripheral Blood Mononuclear Cells (PBMC).
8 mL of blood will be obtained from and arm vein (1 x 8 mL red top tube) for 
serum. 
For children who weigh less than 100 lbs, only 15 mL of blood will be drawn
8.2.4 Blood Volumes in Children
The blood draws in this protocol will impose an upper limit of 3 mL/kg over any 8-week period 
for all pediatric patients.  This volume remains well below the allowed upper limit of 10% of total 
blood volume in an 8-week period as minimal risk. From healthy subjects who weigh at least 
100 pounds, the total amount of blood drawn in any 8 week period is 38 x 3, or 114 mL.  For 
subjects who weigh less than 100 lbs, the total blood drawn will be 45 mL.  Neither of these 
amounts will exceed the limit of 3 mL/kg
DMID 16-[ADDRESS_807759] 4 or more positives in 
any one week for two weeks in a row, and will end when influenza is no longer detected.  During 
influenza season, subjects will be contact[CONTACT_609127].  Subjects who report symptoms meeting the case definition of 
influenza (fever or feverishness plus either cough, rhinitis, or sore throat on the same or 
consecutive days) will be asked to return for an acute illness visit.  At this visit the following 
procedures will take place
Interval medical history will be obtained, including concomitant medications, 
reviewing any new events since the last visit.
The presence and severity of respi[INVESTIGATOR_609116] a visual analog scale.
A combined nasal and throat swab will be obtained for rtRT-PCR detection of 
influenza virus.
If positive, the subject will be invited to participate in the Acute Flu study (DMID 
14-0101) to assess the immune response to infection
8.[ADDRESS_807760] visit will be reviewed, and all concomitant medications will be 
recorded.  A targeted physical examination may be performed, as indicated, and information 
regarding AEs will be solicited. Any ongoing related AEs will be followed to resolution or until a 
stable chronic condition has been established.
Subjects will be encouraged to permit continued follow-up of AEs and to donate scheduled 
blood samples, if possible.
8.4 Unscheduled Visit
Unscheduled visits may occur at any time during the study.  Any of the following activities may 
be performed:
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
17Medical history will be reviewed including concomitant medications, and updated as 
appropriate.
All concomitant medications taken since the study visit will be recorded on the 
appropriate data collection form. Previously recorded medications will be updated as 
appropriate.
Study personnel will discuss with participants and assess and record all AE/SAEs. 
Previously recorded AE/SAEs will be updated as appropriate.
Depending on the reason for the unscheduled visit, vital signs, including oral or axillary 
temperature, pulse, and blood pressure, may be obtained.
If indicated by [CONTACT_9870], a directed physical examination relevant to the interval 
medical history may be performed.
Additional laboratory tests may be obtained depending on the nature of the unscheduled 
visit.
9 STUDY PROCEDURES AND EVALUATIONS
9.1 Clinical Evaluations
Medical History:  Study personnel will take the medical history of all subjects. This history will 
include significant medical disorders of the head, eyes, ears, nose, throat, mouth, 
cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, nervous system, 
blood, lymph glands, endocrine system, musculoskeletal system, skin, and genital/reproductive 
tract.  It will also include a history of allergies, cancer, immunodeficiency, psychiatric illness, 
substance abuse, and autoimmune disease.  Patients will also be queried regarding any 
previous influenza vaccinations, the date and source of vaccine, and the type of vaccine 
administered.  We will use personal history as the primary indicator but will attempt to verify 
vaccination status where possible.
Medication History:  Study personnel will record all medications, including prescription and over-
the-counter drugs (such as vitamins, minerals, supplements, homeopathic preparations and/or 
therapi[INVESTIGATOR_014]), taken by [CONTACT_29276] 30 days prior to enrollment.
Targeted Physical Examination:  Licensed study clinicians (i.e., physician, physician’s assistant, 
nurse practitioner) may conduct a targeted physical examination, if necessary to assist in 
DMID 16-[ADDRESS_807761] vital signs 
(blood pressure, pulse, and oral temperature) measured prior to vaccination.
.
9.2 Laboratory Evaluations/Assays
9.2.1 Immunogenicity Evaluations
Serum hemagglutination-inhibition (HAI).  HAI will be performed in microtiter format using turkey 
RBCs and egg-grown, betapropriolactone-inactivated vaccine viruses as antigen.  The titer of 
antibody will be defined as the highest dilution resulting in complete inhibition of 
hemagglutination.  Sera will be treated with receptor-destroying enzyme and heat inactivated 
prior to testing at an initial starting dilution of 1:4. Sera with no detectable HAI titer will be 
assigned a titer of 1:2 for calculation purposes.
Microneutralization (MN) assay:  Sera will be tested by [CONTACT_609128].  Viral growth will be determined by [CONTACT_609129] a combination of M- and NP-specific monoclonal 
antibodies.  The titer of antibody will be defined as the highest titer resulting in 50% inhibition of 
antigen signal compared to un-neutralized control wells.  Sera will be treated with RDE and heat 
inactivated prior to testing at an initial starting dilution of 1:10. Sera with no neutralizing titer will 
be assigned a value of 1:5 for calculation purposes. 
B cell responses:  Our previous studies have shown that the antibodies secreted by [CONTACT_93247] B 
cells (plasmablasts) and re-activated memory B cells have different specificities and affinities 
that those that accumulate in the serum.  In addition, there is evidence from analyzing secreted 
antibodies that vaccination affects the specificities and improves affinities. Therefore, the 
studies of antibody-secreting (ASC) and memory B cells require the collection of Peripheral 
Blood Mononuclear Cells (PBMC) at different times before and after vaccination for analysis. 
PBMC will be obtained before and on days 0, 7, 28, and [ADDRESS_807762], antibody secreting cells stimulated by [CONTACT_190644], which peak 7 days 
after vaccination in the blood, will be analyzed by [CONTACT_746] B cell ELISPOT assays on plates 
coated with recombinant HA proteins that match the influenza strains in that year’s vaccine.  In 
addition, supernatants   will be collected from cultured plasmablasts for analysis by [CONTACT_35363], MN, 
and ELISA as described above. Memory B cell responses will be assessed similarly at all the 
time points by [CONTACT_609130] B cells in culture [7], performing B cell ELISPOT assays and 
collecting culture supernatants for analysis as described above. The analysis of the ASC and 
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
19memory B cells provides a measure of how the vaccine modifies the B cell repertoire, as well as 
how well someone is responding to the vaccine. 
9.2.2 Specimen Collection, Preparation, Handling and Shippi[INVESTIGATOR_609117], handling, and storage are included in the Manual of 
Procedures (MOP).  
[ADDRESS_807763] of care during influenza vaccine season, following the manufacturers’ 
instructions and safety precautions.
 is a licensed vaccine, NIAID does not expect that any new vaccine related safety signal 
will be detected in this trial.
The National Childhood Vaccine Injury Act (NCVIA) requires  healthcare providers to 
report to VAERS:
Any adverse event listed by [CONTACT_29386] a contraindication to further 
doses of the vaccine; and/or
Any adverse event listed in the VAERS Table of Reportable Events Following 
Vaccination that occurs within the specified time period after vaccination (see below).
oAnaphylaxis or anaphylactic shock (7 days) (see halting criteria) 
oShoulder Injury Related to Vaccine Administration (7 days) 
oVasovagal syncope (7 days)
oGuillain-Barré Syndrome (42 days) 
oAny acute complication or sequelae (including death) of above events (interval - 
not applicable) 
In addition, CDC encourages reporting any serious, unexpected (not listed in product 
label or Investigator’s Brochure), suspected adverse reaction to VAERS and provide a 
copy of the VAERS report to DMID and local IRB as required.

DMID 16-[ADDRESS_807764] the rights and well-being of human subjects in this 
study; to ensure that data are accurate, complete and verifiable from source documents; to ensure 
that conduct is in compliance with the currently approved protocol/amendments, with Good 
Clinical Practice, and with regulatory requirements.
11.[ADDRESS_807765] 
protection, study procedures, laboratory procedures, and data collection processes are of high 
quality and meet sponsor, GCP/ICH, and regulatory guidelines, and that the study is conducted 
in accordance with the protocol and sponsor standard operating procedures. DMID, the 
sponsoring agency, or its designee will conduct site-monitoring visits as defined in the CQMP.
A protocol-specific Clinical Quality Management Plan (CQMP) has been approved for this study 
by [CONTACT_122830]. The Quality Assurance (QA) plan will be implemented by a weekly review of source 
documents by [CONTACT_609131]. The Quality Control 
(QC) plan will be implemented by [CONTACT_609132]’s work 
processes by [CONTACT_464], to ensure that accepted procedures are followed.
Site visits may be made at standard intervals as defined by [CONTACT_149098]. Monitoring visits will include, but are not limited to, review of 
regulatory files, sample tracking log, CRFs, informed consent forms, medical and laboratory 
reports, and protocol compliance. Study monitors will meet with investigators to discuss any 
problems and actions to be taken and document visit findings and discussions.  The University of 
[COMPANY_002]ster’s IRB and other regulatory agencies may conduct study monitoring visits. 
12 STATISTICAL CONSIDERATIONS
12.1 Study Hypothesis
The primary hypothesis being tested in this study is that there will be differences in the 
specificity and magnitude of the HA-specific B cell response depending on the age, previous 
vaccine history and baseline B cell reactivity.
12.2 Sample Size Considerations
Because the degree of variability in many of the measurements in this study are unknown, 
estimating the precision of the correlation of patient characteristics (age and prior vaccination 
history) with outcomes (antibody quality and quantity and B cell response) is not possible.  The 
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
21study will evaluate these outcomes and if trends towards a relationship are discovered 
subsequent studies will evaluate these in more detail.
However, the precision of the estimate of the proportion of subjects who achieve a pre-specified 
number of memory B cells specific for any antigen on day 28 would be determined by [CONTACT_609133].  If there were 30 subjects in any particular age strata, then the half-width of 
the 95% confidence interval for the estimate of the the proportion achieving any level of mBC in 
that strata is shown below
No. of subjects Proportion achieving mBC 
frequencyHalf-width of the 95% CI for 
estimate of proportion
30 10% 10.7%
30 20 14.3
30 30 16.4
30 40 17.5
30 50 17.9
12.3 Planned Interim Analyses (if applicable)
No formal interim analysis is planned.  However, assay results will be reviewed as they become 
available
12.3.1 Safety Review 
NA, no interim analysis of safety is planned.
12.3.2 Immunogenicity or Efficacy Review
NA, no interim analysis of safety is planned.
12.4 Final Analysis Plan 
Data will be analyzed at the end of the year of enrollment.
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
2213 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS
The site will maintain appropriate medical and research records for this study in compliance with 
ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of 
confidentiality of subjects.  The site will permit authorized representatives of the DMID, its 
designees, and appropriate regulatory agencies to examine (and when required by [CONTACT_117574], to copy) clinical records for the purposes of quality assurance reviews, audits and evaluation 
of the study safety and progress.  These representatives will be permitted access to all source 
data which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory 
notes, memoranda, pharmacy dispensing records, recorded data from automated instruments, x-
rays, and subject files kept at the laboratories involved in the study.  CRFs will consist of paper 
document collection forms which will then be entered into the database, and will serve as source 
documents.  All electronic study documents will be secured by [CONTACT_494717]/or password protection.
14 QUALITY CONTROL AND QUALITY ASSURANCE
Following a written DMID-accepted site quality management plan, the site is responsible for 
conducting routine quality assurance (QA) and quality control (QC) activities to internally 
monitor study progress and protocol compliance. 
The Principal Investigators will provide direct access to all study-related field site, source 
documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 
inspection by [CONTACT_3482]. 
The Principal Investigators will ensure all study staff are appropriately trained and current 
documentations are maintained on site.
DMID-designated clinical monitors will verify that the clinical study is conducted and data 
generated, recorded, and reported in compliance with the protocol, GCP, and the applicable 
regulatory requirements. Clinical monitoring reports will be submitted to DMID.
The site staff will implement QC procedures with the data entry system and generate data QC 
checks that will be run on the database. Any missing data or data anomalies will be clarified and 
resolved by [CONTACT_494718]. 
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
2315 ETHICS/PROTECTION OF HUMAN SUBJECTS
15.[ADDRESS_807766]
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the US National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the 
ICH E6; 62 Federal Regulations [ZIP_CODE] (1997).  
15.[ADDRESS_807767] of the subjects’ safety to implement changes prior 
to approval.  The UR IRB operates under U.S. Federal-Wide Assurance (FWA) 
Prior to enrollment of subjects into this trial, the approved protocol and the informed consent 
form will be reviewed and approved by [CONTACT_19821].  Any amendments to the protocol or 
consent materials will also be reviewed and approved by [CONTACT_494719].  Notification of the IRB's composition, or the IRB’s Federal-wide Assurance 
number, will be provided.
Should amendments to the protocol be required, the amendments will be written by [CONTACT_978] [INVESTIGATOR_494665].  The site will submit to the sponsor a 
copy of the IRB letter of approval of the amendment.
15.3 Informed Consent Process
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continuing throughout the individual’s study participation. At the time the study 
staff will seek informed consent, the study worker will ask the eligible participant (or the 
participant’s representative) if the participant is literate.  If the eligible participant reports he or 
she is not literate, then the study staff will request that a witness be present while the study 
worker reads and explains the study and what participation will entail.  If the eligible subject 
accepts to take part in the study, he or she will make a mark on the signature [CONTACT_494724].  The witness will also sign and date the form, if the witness is confident that the participant 
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
24has understood the explanation and is participating willingly.  In addition, the witness will 
complete the date line for the participant.
Extensive discussion of risks and possible benefits of this therapy will be provided to the 
participants and their families.  Consent forms describing in detail the study 
interventions/products, study procedures, and risks are given to the participant and written 
documentation of informed consent is required prior to starting intervention/administering study 
product.  Consent forms will be IRB-approved and the participant will be asked to read and 
review the document. Upon reviewing the document, the investigator will explain the research 
study to the participant and answer any questions that may arise.  The participants will sign the 
informed consent document prior to any procedures being done specifically for the study.  The 
participants should have the opportunity to discuss the study with their families or think about it 
prior to agreeing to participate.  The participants may withdraw consent at any time throughout 
the course of the study.  A copy of the informed consent document will be given to the 
participants for their records.  The rights and welfare of the participants will be protected by 
[CONTACT_26571].
15.3.1 Informed Consent/Assent Process (in Case of a Minor)
Appropriate consent will be obtained from all subjects prior to any study related procedures.  
Adults will sign informed consent, while adolescents ages [ADDRESS_807768] turns 18 during the course of the study, informed consent will be obtained at the next 
study visit.  Consent from a parent or legal guardian will be obtained for children 9 to 12 years of 
age.  Children 9-12 years of age will give verbal assent.
15.4 Exclusion of Women, Minorities, and Children (Special 
Populations)
Because pregnancy could alter the immune response to vaccination, known pregnancy is an 
exclusion to participation.  Otherwise there are no exclusions of special populations.
15.[ADDRESS_807769] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents.  This confidentiality is extended to cover testing of biological 
specimens in addition to the clinical information relating to participants.
DMID 16-[ADDRESS_807770] all documents 
and records required to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study.  The 
clinical study site will permit access to such records.  A representative from the University of 
[COMPANY_002]ster IRB may also have access to the subject’s record. 
15.[ADDRESS_807771] other viruses or bacteria, in order to 
participate. Samples will be stored under this protocol (16-0101) at the local site and will not be 
sold or used directly for production of any commercial product. No human genetic tests will be 
performed on samples.  Each sample will be encoded (labeled) only with a barcode and a 
unique tracking number to protect subject’s confidentiality.  Such testing may be performed by 
[CONTACT_609134].
There are no benefits to subjects in the collection, storage and subsequent research use of 
specimens. Reports about future research done with subject’s samples will NOT be kept in their 
health records, but subject’s samples may be kept with the study records or in other secure 
areas. 
[ADDRESS_807772] KEEPI[INVESTIGATOR_494666], completeness, legibility, and 
timeliness of the data reported. All source documents will be completed in a neat, legible manner 
to ensure accurate interpretation of data using black ink to ensure clarity of reproduced copi[INVESTIGATOR_014].  
When making changes or corrections, the original entry will be crossed out with a single line, 
initialed and dated. The original text will not be erased, overwritten, or altered with correction fluid 
or tape on the original.
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
2616.1 Data Management Responsibilities
All source documents and laboratory reports will be reviewed by [CONTACT_328284], who will ensure that they are accurate and complete.  
Data collection is the responsibility of the clinical study staff at the site under the supervision of 
the clinical PIs.  During the study, the investigators will maintain complete and accurate 
documentation for the study.
16.2 Data Capture Methods
Clinical data will be initially recorded on paper source documents, and then transferred to 
electronic case report forms (eCRF) within BLISS.  Source documents will be retained for 
monitoring purposes in a secure location.  Laboratory data will be directly entered into BLISS 
from laboratory notebooks  
As detailed in the CEIRS contract, overall CEIRS data sharing will adhere to the following 
schedule: 
Sequence data: provided to Data Processing Coordinating Center within 45 days
Surveillance data: provided to Data Processing Coordinating Center within 12 months
Virus phenotypic data: provided to Data Processing Coordinating Center within 12 months
Basic research data: provided to Data Processing Coordinating Center within [ADDRESS_807773] demographics, clinical data, safety assessments, and 
research laboratory results including antibody responses and measurements of B cell 
responses.
16.4 Timing/Reports
The final report will include a comprehensive analysis of the data.
DMID 16-[ADDRESS_807774], the site principal investigator, or other study personnel.  As a result of deviations, 
corrective actions are to be developed by [CONTACT_3483].
These practices are consistent with ICH E6:
4.[ADDRESS_807775]’s source document file.  Protocol 
deviations must be sent to the local IRB/IEC per its guidelines.  The site principal investigator 
[INVESTIGATOR_421228].
[ADDRESS_807776]'s Hospi[INVESTIGATOR_609118]  1979;1:33-
[ADDRESS_807777] Dis  
2013;56:1363-9
3. Keitel WA, Cate TR, Couch RB, Huggins LL and Hess KR. Efficacy of repeated annual 
immunization with inactivated influenza virus vaccines over a five year period Vaccine  
1997;15:1114-22
4. Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, Carter DM, 
Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, Ahmed R, Wilson PC and Hensley 
SE. Immune history shapes specificity of pandemic H1N1 influenza antibody responses The 
Journal of Experimental Medicine  2013;210:1493-1500
5. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le N. M. 
H., Pham Q. T., Tran N. D., Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le T. T., van der 
Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N, de Jong JC, Palache 
A, Beyer WEP, Le Q. M., Nguyen T. H., Wertheim HFL, Hurt AC, Osterhaus ADME, Barr IG, 
Fouchier RAM, Horby [CONTACT_609135]. Antibody landscapes after influenza virus infection or 
vaccination Science  2014;346:996-1000
6. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E and Chen RT. 
Guilllain-Barre syndrome following influenza vaccination JAMA  2004;292:2478-[ADDRESS_807778], Glidewell J and Ahmed R. Tracking human antigen-specific memory B 
cells:  a sensitive and generalized ELISPOT system Journal of Immunological Methods  
2004;286:111-122
DMID 16-0101 Age and response to flu vaccines Version 5.0
25 January 2021
_____________________________________________________________________________________________
_____________________________________________________________________________________________
2919 SUPPLEMENT/APPENDICES
Table of procedures by [CONTACT_609136]
 V1 V2 V3  V4   
Procedure D0 D7 D28D48, 
D62, 
D76 D90 D104D118, 
D132, 
D146, 
D160, 
D174, 
D188Flu**
Illness
Informed Consent X        
Medical History X        
Interim History  X X  X   X
Concomitant Meds X X X  X   X
Targeted physical exam* X X X  X   X
Review Enrollment Criteria X        
Peripheral blood (mL)*** 38  38 38   38    
Administer Vaccine X        
30 minute observation X        
Review Adverse Events X X X      
Flu surveillance phone call    X  X X  
NP swab for flu PCR        X
*As indicated by [CONTACT_609137] (see protocol for definition)
** Subjects reporting flu-like symptoms will be asked to make an influenza visit
*** Blood drawing in children will not exceed 3 mL/kg in any 8 week period